TUCSON, Ariz.--(BUSINESS WIRE)--Dec. 16, 2005--ImaRx Therapeutics, Inc., a biopharmaceutical company developing innovative solutions for stroke and vascular disease, today announced the closing of an equity financing, raising approximately $15 million in gross proceeds. The capital will be used for general corporate purposes, to fund product acquisitions, and to advance the clinical trials of the Company’s lead products.
